Docetaxel Bests Paclitaxel in Metastatic Breast Cancer
November 01, 2003
COPENHAGEN, Denmark-In the first head-to-head comparison of the two taxanes, docetaxel (Taxotere) produced significantly longer survival in patients with metastatic breast cancer, compared with paclitaxel (Taxol), but at the cost of increased toxicity. Peter Ravdin, MD, PhD, clinical professor of medicine, The University of Texas Health Science Center, San Antonio, and principal investigator of the study, presented the phase III findings at ECCO 12, the European Cancer Conference (abstract 670). The study was sponsored by Aventis, manufacturer of Taxotere.